A randomised controlled trial to compare minimally invasive glucose monitoring devices with conventional monitoring in the management of insulin-treated diabetes mellitus (MITRE)

Health Technology Assessment

Volumn 13, Issue 28, 2009, Pages

  Newman, S P ^a   Cooke, D ^a   Casbard, A ^b   Walker, S ^c   Meredith, S ^b   Nunn, A ^b   Steed, L ^a   Manca, A ^c   Sculpher, M ^c   Barnard, M ^d   Kerr, D ^e   Weaver, J ^f   Ahlquist, J ^g   Hurel, S J ^h  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

^d WHITTINGTON HOSPITAL   (United Kingdom)

^e ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^f QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^g SOUTHEND HOSPITAL   (United Kingdom)

^h UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; NATEGLINIDE; REPAGLINIDE;

APPLICATION SITE DISCOMFORT; APPLICATION SITE INFLAMMATION; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLOOD GLUCOSE MONITORING; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEVICE; DIABETES MELLITUS; DRUG COST; DRY SKIN; FEEDBACK SYSTEM; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH PROGRAM; HEALTH SERVICE; HEALTH STATUS; HUMAN; HYPERGLYCEMIA; HYPERPIGMENTATION; HYPOGLYCEMIA; HYPOPIGMENTATION; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; LONG TERM CARE; MINIMALLY INVASIVE PROCEDURE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREVALENCE; PRINCIPAL COMPONENT ANALYSIS; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RISK FACTOR; SCORING SYSTEM; SELF REPORT; SHORT COURSE THERAPY; SKIN EDEMA; SKIN INFLAMMATION; SKIN IRRITATION; SKIN MANIFESTATION; SOCIAL PSYCHOLOGY;

EID: 70350753026     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta13280     Document Type: Review

References (132)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes - estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053
2. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14:S7-85. (Pubitemid 28020378)
3. Williams R, Wild S. Diabetes prevalence data for the United Kingdom - what do we have and what do we need? Diabet Med 2003;20:505-506 (Pubitemid 36776015)
4. Zimmet PZ. Diabetes epidemiology as a tool to trigger diabetes research and care. Diabetologia 1999;42:499-518.
5. Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technol Assess 2004;8:1-186. (Pubitemid 39585967)
6. Burden AC, Hearnshaw JR, Swift PGF. Childhood diabetes mellitus - an increasing incidence. Diabet Med 1989;6:334-336 (Pubitemid 19113738)
7. Rangasami JJ, Greenwood DC, McSporran B, Smail PJ, Patterson CC, Waugh NR. Rising incidence of type 1 diabetes in Scottish children, 1984-1993. Arch Dis Child 1997;77:210-213
8. Turner RC, Holman RR, Cull CA, Stratton IM, Matthews DR, Frighi V, et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853 (Pubitemid 28416718)
9. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-787 (Pubitemid 34000780)
10. Wanless D. Securing our future health: taking a long-term view. London: HM Treasury; 2002.
11. King's Fund. TARDIS: type 2 diabetes: accounting for a major resource demand in society in the UK. London: Kings Fund; 2000.
12. International Diabetes Federation. Cost-effective approaches to diabetes care and prevention. Brussels: IDF Task Force on Diabetes Health Economics; 2003.
13. Raleigh VS, Kiri V, Balarajan R. Variations in mortality from diabetes mellitus, hypertension and renal disease in England and Wales by country of birth. Health Trends 1996;28:122-127
14. Matthews DR, Pramming S. Diabetes and the global burden of non-communicable disease. Lancet 2003;362:1763-1764 (Pubitemid 37468334)
15. Shillitoe R. Diabetes mellitus. In Broome A, Llewellyn S, editors. Health psychology: processes and applications. 2nd edn. London: Chapman & Hall; 1995. pp. 187-204.
16. Hanninen JA, Takala JK, Keinanen-Kiukaanniemi SM. Depression in subjects with type 2 diabetes - predictive factors and relation to quality of life. Diabetes Care 1999;22:997-998
17. Wandell PE, Tovi J. The quality of life of elderly diabetic patients. J Diabetes Complications 2000;14:25-30. (Pubitemid 30484035)
18. de Visser CL, Bilo HJG, Groenier KH, de Visser W, Meyboom-de Jong B. The influence of cardiovascular disease on quality of life in type 2 diabetics. Qual Life Res 2002;11:249-261 (Pubitemid 34553505)
19. Goddijn PPM, Bilo HJG, Feskens EJM, Groenier KH, van der Zee KI, Meyboom-de Jong B. Longitudinal study on glycaemic control and quality of life in patients with Type 2 diabetes mellitus referred for intensified control. Diabet Med 1999;16:23-30.
20. Hoey H, Aanstoot HJ, Chiarelli F, Daneman D, Danne T, Dorchy H, et al. Good metabolic control is associated with better quality of life in 2,101 adolescents with type 1 diabetes. Diabetes Care 2001;24:1923-1928 (Pubitemid 33716502)
21. Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev 1999;15:205-218
22. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
23. Cleary PA, Backlund JYC, Genuth SM, Lachin JM, Orchard TJ, Raskin P, et al. Intensive diabetes with type 1 diabetes. N Engl J Med 2005;353:2643-2653
24. Farmer A, Wade A, Goyder E, Yudkin P, French D, Craven A, et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. Br Med J 2007;335:132-136 (Pubitemid 47172232)
25. Gulliford M. Self monitoring of blood glucose in type 2 diabetes. Br Med J 2008;336:1139-1140 (Pubitemid 351809253)
26. O'Kane MJ, Coates VE, Bunting B. The efficacy of self blood glucose monitoring in type 2 diabetes: the ESMON Study. Diabetologia 2006;49:550.
27. Simon J, Gray AM, Clarke P, Wade A, Neil A, Farmer A, et al. Cost-effectiveness of self-monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial. Br Med J 2008;336:1177-1180 (Pubitemid 351809279)
28. Coster S, Gulliford MC, Seed PT, Powrie JK, Swaminathan R. Self-monitoring in Type 2 diabetes mellitus: a meta-analysis. Diabet Med 2000;17:755-761 (Pubitemid 32000973)
29. Kirk JK, Rheney C. Important features of blood glucose meters. J Am Pharm Assoc 1998;38:210-219
30. Bode BW, Sabbah H, Davidson PC. What's ahead in glucose monitoring? New techniques hold promise for improved ease and accuracy. Postgrad Med 2001;109:41-49 (Pubitemid 32298998)
31. Bolinder J, HagstromToft E, Ungerstedt U, Arner P. Self-monitoring of blood glucose in type I diabetic patients: comparison with continuous microdialysis measurements of glucose in subcutaneous adipose tissue during ordinary life conditions. Diabetes Care 1997;20:64-70. (Pubitemid 27020043)
32. Boland EA, Tamborlane WV. Continuous glucose monitoring in youth with type 2 diabetes: overcoming barriers to successful treatment. Diabetes Technol Ther 2000;2(Suppl.1):S53-9.
33. Ginsberg BH. An overview of minimally invasive technologies. Clin Chem 1992;38:1596-1600
34. Klonoff DC. Noninvasive blood glucose monitoring. Diabetes Care 1997;20:433-437
35. Cefalu WT, Weir GC. New technologies in diabetes care. Patient Care 2003;37:66-78.
36. Pfutzner A, Caduff A, Larbig M, Schrepfer T, Forst T. Impact of posture and fixation technique on impedance spectroscopy used for continuous and noninvasive glucose monitoring. Diabetes Technol Ther 2004;6:435-441 (Pubitemid 39121366)
37. Weinzimer SA. PENDRA: the once and future noninvasive continuous glucose monitoring device? Diabetes Technol Ther 2004;6:442-444
38. Wentholt IM, Hoekstra JB, Zwart A, DeVries JH. Pendra goes Dutch: lessons for the CE mark in Europe. Diabetologia 2005;48:1055-1058 (Pubitemid 40909638)
39. Garg SK, Potts RO, Ackerman NR, Fermi SJ, Tamada JA, Chase HP. Correlation of fingerstick blood glucose measurements with GlucoWatch biographer glucose results in young subjects with type 1 diabetes. Diabetes Care 1999;22:1708-1714
40. Tamada JA, Garg S, Jovanovic L, Pitzer KR, Fermi S, Potts RO. Noninvasive glucose monitoring: comprehensive clinical results. Cygnus Research Team. JAMA 1999;282:1839-1844
41. Gross TM, Bode BW, Einhorn D, Kayne DM, Reed JJ, White NH, et al. Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use. Diabetes Technol Ther 2000;2:49-56. (Pubitemid 30256421)
42. Rebrin K, Steil GM, Van Antwerp WP, Mastrototaro JJ. Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring. Am J Physiol 1999;277:E561-71. (Pubitemid 29458218)
43. Maran A, Poscia A. Continuous subcutaneous glucose monitoring: the GlucoDay system. Diabetes Nutr Metab 2002;15:429-433 (Pubitemid 36410449)
44. Feldman B, Brazg R, Schwartz S, Weinstein R. A continuous glucose sensor based on wired enzyme technology - results from a 3 day trial in patients with type 1 diabetes. Diabetes Technol Ther 2003;5:769-779 (Pubitemid 37339539)
45. Bailey TS, Zisser HC, Garg SK. Reduction in hemoglobin A1c with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther 2007;9:203-210
46. Bode BW, Gross TM, Thornton KR, Mastrototaro JJ. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Res Clin Pract 1999;46:183-190
47. Broz J, Andel M. Continuous glucose monitoring can help to decrease frequency of symptomatic hypoglycaemia in patients with type 1 diabetes treated with CSII in long term follow-up. Diabetes 2002;51:A119.
48. Chase HP, Kim LM, Owen SL, MacKenzie TA, Klingensmith GJ, Murtfeldt R, et al. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics 2001;107:222-226 (Pubitemid 32121233)
49. Chase HP, Roberts MD, Wightman C, Klingensmith G, Garg SK, Van Wyhe M, et al. Use of the GlucoWatch biographer in children with type 1 diabetes. Pediatrics 2003;111:790-794 (Pubitemid 36402903)
50. Chico A, Vidal-Rios P, Subira M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 2003;26:1153-1157 (Pubitemid 36929264)
51. Deiss D, Hartmann R, Schmidt J, Kordonouri O. Results of a randomised controlled cross-over trial on the effect of continuous subcutaneous glucose monitoring (CGMS) on glycaemic control in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes 2006;114:63-67
52. Deiss D, Bolinder J, Riveline P, Battelino T, Bosi E, Tubiana Rufi N, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 2006;29:2730-2732 (Pubitemid 44912209)
53. DirecNet Group. A randomized multicenter trial comparing the GlucoWatch Biographer with standard glucose monitoring in children with type 1 diabetes. Diabetes Care 2005;28:1101-1106
54. DirecNet Group. Continuous glucose monitoring in children with type 1 diabetes. J Pediatr 2007;151:388-393
55. Hathout E, Patel N, Southern C, Hill J, Anderson R, Sharkey J, et al. Home use of the GlucoWatch G2 biographer in children with diabetes. Pediatrics 2005;115:662-666 (Pubitemid 43373026)
56. Jeha GS, Karaviti LP, Anderson B, Smith EO, Donaldson S, McGirk TS, et al. Continuous glucose monitoring and the reality of metabolic control in preschool children with type 1 diabetes. Diabetes Care 2004;27:2881-2886 (Pubitemid 39565053)
57. Kaufman FR, Gibson LC, Halvorson M, Carpenter S, Fisher LK, Pitukcheewanont P. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care 2001;24:2030-2034 (Pubitemid 33716516)
58. Lagarde WH, Barrows FP, Davenport ML, Kang MS, Guess HA, Calikoglu AS. Continuous subcutaneous glucose monitoring in children with type 1 diabetes mellitus: a single-blind, randomized, controlled trial. Pediatr Diabetes 2006;7:159-164 (Pubitemid 43916285)
59. Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics 2003;111:933-938 (Pubitemid 36542603)
60. Sabbah H, Bode BW, McCulloch K. A randomized, controlled study: use of a continuous glucose sensor improves HbA1c levels. Diabetologia 2001;44:A239.
61. Salardi S, Zucchini S, Santoni R, Ragni L, Gualandi S, Cicognani A, et al. The glucose area under the profiles obtained with continuous glucose monitoring system relationships with NbA(lc) in pediatric type-1 diabetic patients. Diabetes Care 2002;25:1840-1844 (Pubitemid 41071097)
62. Schaepelynck-Belicar P, Vague P, Simonin G, Lassmann-Vague V. Improved metabolic control in diabetic adolescents using the continuous glucose monitoring system (CGMS). Diabetes Metab 2003;29:608-612 (Pubitemid 38082163)
63. Schiaffini R, Ciampalini P, Fierabracci A, Spera S, Borrelli P, Bottazzo GF, et al. The Continuous Glucose Monitoring System (CGMS) in type 1 diabetic children is the way to reduce hypoglycemic risk. Diabetes Metab Res Rev 2002;18:324-329
64. Tanenberg R, Bode B, Lane W, Levetan C, Mestman J, Harmel AP, et al. Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clin Proc 2004;79:1521-1526 (Pubitemid 39578876)
65. Weinzimer S, Xing D, Tansey M, Fiallo-Scharer R, Mauras N, Wysocki T, et al. FreeStyle Navigator Continuous Glucose Monitoring System use in children with type 1 diabetes using glargine-based multiple daily dose regimens - results of a pilot trial diabetes research in children network (DirecNet) study group. Diabetes Care 2008;31:525-527
66. Yates K, Milton AH, Dear K, Ambler G. Continuous glucose monitoring-guided insulin adjustment in children and adolescents on near-physiological insulin regimens - a randomized controlled trial. Diabetes Care 2006;29:1512-1517 (Pubitemid 44127573)
67. Technology Evaluation Center. Use of intermittent or continuous interstitial fluid glucose monitoring in patients with diabetes mellitus. Report No. 18. Iowa: Blue Cross and Blue Shield Association; 2003.
68. Klonoff DC. A review of continuous glucose monitoring technology. Diabetes Technol Ther 2005;7:770-775 (Pubitemid 41572080)
69. Tavris DR, Shoaibi A. The public health impact of the MiniMed Continuous Glucose Monitoring System (CGMS) - an assessment of the literature. Diabetes Technol Ther 2004;6:518-522 (Pubitemid 39121379)
70. Reach G. Continuous glucose monitoring and diabetes health outcomes: a critical appraisal. Diabetes Technol Ther 2008;10:69-80. (Pubitemid 351230288)
71. Wentholt IME, Hoekstra JBL, De Vries JH. Continuous glucose monitors: the long-awaited watchdogs? Diabetes Technol Ther 2007;9:399-409.
72. Golicki DT, Golicka D, Groele L, Pankowska E. Continuous Glucose Monitoring System in children with type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetologia 2008;51:233-240
73. McCreadie C, Tinker A. The acceptability of assistive technology to older people. Ageing Soc 2005;25:91-110. (Pubitemid 40263019)
74. Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 2001;24:1858-1862 (Pubitemid 33716491)
75. Guerci B, Floriot M, Bohme P, Durain D, Benichou M, Jellimann S, et al. Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous insulin infusion using insulin analogs. Diabetes Care 2003;26:582-589 (Pubitemid 36929311)
76. Gross TM, Mastrototaro JJ. Efficacy and reliability of the continuous glucose monitoring system. Diabetes Technol Ther 2000;2(Suppl.1):S19-26.
77. Maia FFR, Araujo LR. Efficacy of continuous glucose monitoring system (CGMS) to detect postprandial hyperglycemia and unrecognized hypoglycemia in type 1 diabetic patients. Diabetes Res Clin Pract 2007;75:30-34
78. Weintrob N, Schechter A, Benzaquen H, Shalitin S, Lilos P, Galatzer A, et al. Glycemic patterns detected by continuous subcutaneous glucose sensing in children and adolescents with type 1 diabetes mellitus treated by multiple daily injections vs continuous subcutaneous insulin infusion. Arch Pediatr Adolesc Med 2004;158:677-684 (Pubitemid 38886494)
79. Yogev Y, Chen R, Ben Haroush A, Phillip M, Jovanovic L, Hod M. Continuous glucose monitoring for the evaluation of gravid women with type 1 diabetes mellitus. Obstet Gynecol 2003;101:633-638 (Pubitemid 36390048)
80. NICE. Guide to the methods of technology appraisal. London: NICE; 2004.
81. Jadviscokova T, Fajikusova Z, Pallayova M, Luza J, Kuzmina G. Occurrence of adverse events due to continuous glucose monitoring. Biomed Pap Med Fac Univ Palacky Olomouc Czech Republic 2007;151:263-266
82. Bozzetti V, Viscardi M, Bonfanti R, Azzinari A, Meschi F, Bognetti E, et al. Results of continuous glucose monitoring by GlucoWatch Biographer in a cohort of diabetic children and adolescents under real-life conditions. Pediatr Diabetes 2003;4:57-58 (Pubitemid 36621668)
83. DirecNet Group. The accuracy of the GlucoWatch G2 biographer in children with type 1 diabetes: results of the diabetes research in children network (DirecNet) accuracy study. Diabetes Technol Ther 2003;5:791-800. (Pubitemid 37339541)
84. Gandrud LM, Paguntalan HU, Van Wyhe MM, Kunselman BL, Leptien AD, Wilson DM, et al. Use of the Cygnus GlucoWatch biographer at a diabetes camp. Pediatrics 2004;113:108-111
85. Tamada JA, Davis TL, Leptien AD, Lee J, Wang B, Lopatin M, et al. The effect of preapplication of corticosteroids on skin irritation and performance of the GlucoWatch G2 Biographer. Diabetes Technol Ther 2004;6:357-367 (Pubitemid 38821621)
86. Tierney MJ, Tamada JA, Potts RO, Jovanovic L, Garg S. Clinical evaluation of the GlucoWatch biographer: a continual, non-invasive glucose monitor for patients with diabetes. Biosens Bioelectron 2001;16:621-629 (Pubitemid 33000190)
87. Esmatjes E, Flores L, Vidal M, Rodriguez L, Cortes A, Almirall L, et al. Hypoglycaemia after pancreas transplantation: usefulness of a continuous glucose monitoring system. Clin Transplant 2003;17:534-538 (Pubitemid 37461432)
88. Maran A, Crepaldi C, Tiengo A, Grassi G, Vitali E, Pagano G, et al. Continuous subcutaneous glucose monitoring in diabetic patients: a multicenter analysis. Diabetes Care 2002;25:347-352 (Pubitemid 41079634)
89. Wong LJ, Buckingham BA, Kunselman B, Istoc E, Leach J, Purvis R. Extended use of a new continuous glucose monitoring system with wireless data transmission in children with type 1 diabetes mellitus. Diabetes Technol Ther 2006;8:139-145 (Pubitemid 43848036)
90. Jungheim K, Wientjes KJ, Heinemann L, Lodwig V, Koschinsky T, Schoonen AJ. Subcutaneous continuous glucose monitoring: feasibility of a new microdialysis-based glucose sensor system. Diabetes Care 2001;24:1696-1697
91. Garg S, Jovanovic L. Relationship of fasting and hourly blood glucose levels to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Diabetes Care 2006;29:2644-2649 (Pubitemid 44912192)
92. Garg SK, Schwartz S, Edelman SV. Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care 2004;27:734-738 (Pubitemid 38280542)
93. Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor. Diabetes Care 2006;29:44-50.
94. Burdick J, Chase P, Faupel M, Schultz B, Gebhart S. Real-time glucose sensing using transdermal fluid under continuous vacuum pressure in children with type 1 diabetes. Diabetes Technol Ther 2005;7:448-455 (Pubitemid 40847807)
95. Kubiak T, Worle B, Kuhr B, Nied I, Glasner G, Hermanns N, et al. Microdialysis-based 48-hour continuous glucose monitoring with GlucoDay: clinical performance and patients' acceptance. Diabetes Technol Ther 2006;8:570-575 (Pubitemid 44946881)
96. Cauza E, Hanusch-Enserer U, Strasser B, Ludvik B, Kostner K, Dunky A, et al. Continuous glucose monitoring in diabetic long distance runners. Int J Sports Med 2005;26:774-780 (Pubitemid 41658613)
97. Hay LC, Wilmshurst EG, Fulcher G. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. Diabetes Technol Ther 2003;5:19-26. (Pubitemid 36506086)
98. McLachlan K, Jenkins A, O'Neal D. The role of continuous glucose monitoring in clinical decisionmaking in diabetes in pregnancy. Aust N Z J Obstet Gynaecol 2007;47:186-190 (Pubitemid 46909296)
99. DirecNet Group. Youth and parent satisfaction with clinical use of the GlucoWatch G2 Biographer in the management of pediatric type 1 diabetes. Diabetes Care 2005;28:1929-1935
100. Bode B, Gross K, Rikalo N, Schwartz S, Wahl T, Page C, et al. Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the guardian continuous monitoring system. Diabetes Technol Ther 2004;6:105-113 (Pubitemid 38445735)
101. Boland EA, DeLucia MC, Brandt CA, Ahern JJ, Tamborlane WV. Repeated use of the continuous glucose monitoring system (CGMS) in children with well-controlled TIDM decreases the frequency of nocturnal hypoglcyemia without sacrificing metabolic control. Diabetes 2002;51:A119.
102. Gillespie R. Manufacturing knowledge: a history of the Hawthorne experiments. Cambridge: Cambridge University Press; 1991.
103. Heinemann L, Koschinsky T. Continuous glucose monitoring: an overview of today's technologies and their clinical applications. Int J Clin Pract Suppl 2002;129:75-79 (Pubitemid 34839469)
104. Freedman N. CGMS accuracy. Insulin Pumpers UK; 2001. URL: www.insulin-pumpers.org.uk/cgmsaccuracy/.
105. Cameron FJ, Ambler GR. Does continuous glucose monitoring have clinical utility in contemporary management of diabetes? J Paediatr Child Health 2004;40:79-84.
106. Heinemann L. Glucose monitoring: today and tomorrow. Infusystems Int 2004;3:9-14.
107. McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. Diabet Med 2001;18:690-705.
108. Bradley C, Todd C, Gorton T, Symonds E, Martin A, Plowright R. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual Life Res 1999;8:79-91. (Pubitemid 29362749)
109. Toobert DJ, Hampson SE, Glasgow RE. The summary of diabetes self-care activities measure - results from 7 studies and a revised scale. Diabetes Care 2000;23:943-950
110. Cox DJ, Irvine A, Gonderfrederick L, Nowacek G, Butterfield J. Fear of hypoglycemia - quantification, validation, and utilization. Diabetes Care 1987;10:617-621 (Pubitemid 17158936)
111. Bradley C. Diabetes treatment satisfaction questionnaire. In Bradley C, editor. Handbook of psychology and diabetes. Chur, Switzerland: Harwood Academic Publishers; 1994. pp. 111-132
112. Bradley C, Plowright R, Stewart J, Witthaus E. Diabetes treatment satisfaction questionnaire (change) in English and German evaluated in insulin glargine trials. Diabetologia 2000;43:A196.
113. Barendse S, Speight J, Bradley C. The ADDLoC (Audit of Diabetes-Dependent Locus of Control): positive and negative outcomes in a balanced measure. Proc Br Psychol Soc 2000;8:12.
114. Hampson SE, Glasgow RE, Strycker LA. Beliefs versus feelings: a comparison of personal models and depression for predicting multiple outcomes in diabetes. Br J Health Psychol 2000;5:27-40.
115. Glasgow RE, Hampson SE, Strycker LA, Ruggiero L. Personal-model beliefs and social-environmental barriers related to diabetes self-management. Diabetes Care 1997;20:556-561 (Pubitemid 27143415)
116. Hampson SE, Glasgow RE, Foster LS. Personal models of diabetes among older adults - relationship to self-management and other variables. Diabetes Educ 1995;21:300-307
117. Drummond MF, Sculpher MJ, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford Medical Publications; 2005.
118. Kind P. The EuroQol instrument: an index of health-related quality of life. In Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadephia, PA: Lipincott-Raven; 1996.
119. Information Centre for Health and Social Care. Prescription cost analysis: England 2004. London: Department of Health; 2005.
120. Euroqol. URL: www.euroqol.org. Cited 26 May 2008.
121. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK general population survey. Centre for Health Economics discussion paper. York: University of York Centre for Health Economics; 1995.
122. Royston P. Multiple imputation of missing values. Stata J 2004;4:227-241
123. Barber JA, Thompson SG. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy 2004;9:197-204. (Pubitemid 39424759)
124. Bradley C, Gamsu DS, Moses JL, Knight G, Boulton AJM, Drury J, et al. The use of diabetes-specific perceived control and health belief measures to predict treatment choice and efficacy in a feasibility study of continuous subcutaneous insulin infusion pumps. Psychol Health 1987;1:133-146
125. Eastman RC, Leptien AD, Chase HP. Cost-effectiveness of use of the GlucoWatch Biographer in children and adolescents with type 1 diabetes: a preliminary analysis based on a randomized controlled trial. Pediatr Diabetes 2003;4:82-86
126. Watson JM, Torgerson DJ. Increasing recruitment to randomised trials: a review of randomised controlled trials. BMC Med Res Methodol 2006;6:34.
127. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. Br Med J 2002;325:746.
128. Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescott R. Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol 1999;52:1143-1156 (Pubitemid 29535414)
129. Costenbader KH, Brome D, Blanch D, Gall V, Karlson E, Liang MH. Factors determining participation in prevention trials among systemic lupus erythematosus patients: a qualitative study. Arthritis Rheum 2007;57:49-55. (Pubitemid 46256724)
130. Todd C, Bradley C. Evaluating the design and development of psychological scales. In Bradley C, editor. Handbook of psychology and diabetes: a guide to psychological measurement in diabetes research and practice. Chur, Switzerland: Harwood Academic Publishers. pp. 15-42.
131. Richie J, Spencer L. Qualitative data analysis for applied policy research. In Bryman A, Burgess RG, editors. Analysing qualitative data. London: Routledge. pp. 173-194
132. McGee HM, O'Boyle CA, Hickey A, O'Malley K, Joyce CR. Assessing the quality of life of the individual: the SEIQoL with a healthy and a gastroenterology unit population. Psychol Med 1991;21:749-759